Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  Issue: December 2021  |  December 16, 2021

Figure 1A

Figure 1A

No universal guidelines for the treatment of ICI-arthritis exist, but some suggestions follow. Management should always be discussed with the patient’s treating oncologist, especially if the patient is enrolled in a clinical trial.

For mono- or oligoarticular arthritis, intra-articular steroid injections can be helpful. For grade 1 arthritis, acetaminophen or non-steroidal anti-inflammatory drugs can be used. Low-dose corticosteroids (5–20 mg prednisone equivalent) can also be considered, tapering to the minimum required dose for symptom relief. (Note: Most oncology trial protocols allow patients to use the equivalent of up to 10 mg of prednisone daily and remain in the study.)

Figure 1B

Figure 1B

Immunomodulating disease-modifying anti-rheumatic drugs (DMARDs), such as hydroxychloroquine or sulfasalazine, can also be used to help taper corticosteroids, with the goal of bringing daily prednisone down to 10 mg or less.7 ICI therapy does not need to be held in mild, grade 1 cases.

For grade 2 arthritis, prednisone doses as high as 20–40 mg daily may be required. ICI treatment should generally be held until the arthritis has been controlled to a grade 1 level and prednisone has been tapered to 10 mg or less daily.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Grade 3 arthritis requires up to 40–60 mg of prednisone daily, and the ICI should be discontinued. The National Comprehensive Cancer Network guidelines recommend rheumatology consultation and DMARD use for arthritis that does not respond to corticosteroids alone—after four

Figure 1C

Figure 1C

Histopathology from bilateral total knee arthroplasty of a patient with bilateral ICI-arthritis. A) There is synovial infiltration by neutrophils and macrophages and fibrin deposition, but no necrosis. B) Pannus containing neutrophils, macrophages and few lymphocytes and plasma cells. There is articular cartilage destruction and bone erosion. C) Second knee explant with papillary processes of synovium showing many lymphoid aggregates, a few germinal centers and some neutrophils in the lining layer.

weeks for grade 2 arthritis and after two weeks for grade 3 arthritis.8

We favor early tumor necrosis factor (TNF) inhibition for high-grade arthritis because ICI-arthritis tends to persist for many months, and TNF inhibitors can significantly reduce corticosteroid exposure.9 Methotrexate can also be used, but its delayed onset of action and broad, rather than targeted, immunosuppressive effects are disadvantages. IL-6R blockers have also been used successfully, but less data are available on their safety and efficacy.10

Future studies should compare the safety and efficacy of corticosteroids vs. TNF inhibitors vs. methotrexate in the context of ICI-arthritis.

Case 2

A 53-year-old woman with metastatic renal cell carcinoma presents to the emergency department with neck weakness, ptosis and severe proximal myalgias shortly after her second pembrolizumab (an anti-PD-1) infusion. How should you evaluate and manage her?

ICI-Myositis & Myocarditis

Rheumatologists may not immediately recognize this patient’s atypical presentation, but the muscle weakness and myalgias should raise suspicion of a potential myositis. ICI-myositis has been described in 0.4% of patients treated with ICIs.11

In contrast to the usually painless, subacute proximal muscle weakness seen in idiopathic inflammatory myopathies, ICI-myositis is often characterized by severe myalgia, sometimes with a lesser degree of weakness. Creatinine kinase (CK) elevation varies. A myasthenia-like distribution of muscle weakness, including ocular, bulbar and/or paraspinal muscles, can be present, but patients do not typically respond to pyridostigmine (see Figure 2).12,13

Muscle biopsy specimens demonstrate infiltrating T cells, myophagocytosis and necrotic myofibers.12

For patients with ICI-myositis, death is most commonly due to respiratory failure, presumably due to involvement of respiratory muscles; however, interstitial lung disease is uncommon.11 In addition to having features of myasthenia, ICI-myositis patients can have concomitant myocarditis, leading to conduction abnormalities and/or acute heart failure with fatality rates well over 50%.11,14

ICI-myositis tends to occur within two months of ICI initiation, although it can occur later as well. As with other irAEs, the most severe cases most frequently occur soon after treatment with the ICI begins. ICI-myositis, myasthenia and myocarditis are more common in those treated with combination ICIs (e.g., concurrent use of an anti-PD-L1 and an anti-CTLA-4) than in those treated with monotherapy.

ICI-Myositis & Myocarditis Management

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Conditions Tagged with:immune checkpoint inhibitor (ICI)immune-related adverse events

Related Articles
    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

    Immune Checkpoint Inhibitors & Immune-Related Adverse Events

    September 20, 2018

    Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

    ACR Convergence graphic

    Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

    December 4, 2020

    Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.

    Insights into Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

    July 29, 2020

    Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences